Quantbot Technologies LP Boosts Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Quantbot Technologies LP lifted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 47.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,237 shares of the biopharmaceutical company’s stock after purchasing an additional 3,636 shares during the period. Quantbot Technologies LP’s holdings in Catalyst Pharmaceuticals were worth $235,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also made changes to their positions in the company. Steward Partners Investment Advisory LLC purchased a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth about $27,000. Farther Finance Advisors LLC lifted its stake in Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 1,495 shares in the last quarter. Larson Financial Group LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 2,994 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $65,000. Finally, KBC Group NV lifted its position in Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 1,542 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now directly owns 68,873 shares in the company, valued at $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is owned by insiders.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $24.69 on Friday. The firm has a market cap of $3.00 billion, a P/E ratio of 20.92, a P/E/G ratio of 3.31 and a beta of 0.84. The firm’s 50 day moving average price is $22.66 and its 200-day moving average price is $21.81. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $26.16.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CPRX. Stephens restated an “overweight” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Finally, Bank of America reiterated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $32.29.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.